Abstract | Monocytes are heterogeneous effector cells involved in the maintenance and restoration of tissue integrity. Monocytes and macrophages are involved in cardiovascular disease progression, and are associated with the development of unstable atherosclerotic plaques. Hyperlipidaemia can accelerate cardiovascular disease progression. However, monocyte responses to hyperlipidaemia are poorly understood. In the past decade, accumulating data describe the relationship between the dynamic blood lipid environment and the heterogeneous circulating monocyte pool, which might have profound consequences for cardiovascular disease. In this Review, we explore the updated view of monocytes in cardiovascular disease and their relationship with macrophages in promoting the homeostatic and inflammatory responses related to atherosclerosis. We describe the different definitions of dyslipidaemia, highlight current theories on the ontogeny of monocyte heterogeneity, discuss how dyslipidaemia might alter monocyte production, and explore the mechanistic interface linking dyslipidaemia with monocyte effector functions, such as migration and the inflammatory response. Finally, we discuss the role of dietary and endogenous lipid species in mediating dyslipidaemic responses, and the role of these lipids in promoting the risk of cardiovascular disease through modulation of monocyte behaviour. NATURE REVIEWS | CARDIOLOGY VOLUME 14 | JULY 2017 | 387 REVIEWS © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
Investigation of monocytes and macrophages has had a resurgence of activity over the past 10 years. This increase in monocyte and macrophage research is a result of a refinement of the definition and character ization of the mononuclear phagocyte system. These phagocytes make up diverse populations of cells with tissuespecific specialization to maintain homeostasis, such as Kupffer cells in the liver and alveolar macro phages in the lungs 1 . Some of these tissue specific macro phages can maintain their population lev els through in situ proliferation, and do not require continuous replenishment via blood monocytes 2 . Therefore, the role of blood monocytes as shortlived macrophage precursors might need redefinition and deeper character ization. Moreover, monocyte popu lations are hetero geneous and have subsetspecific effector functions 3 , which are altered as a result of changes in the local environment and inflammatory response. This Review focuses on dyslipidaemia and changes in blood lipid profiles that might alter the behaviour of monocytes, thereby contributing to cardiovascular disease.
Steady-state production and function

Origin of tissue-resident macrophages
The identification of fetalderived, selfmaintaining, tissueresident macrophages has shifted our under standing of myeloid lineages away from the previously accepted dogma, which postulated as the core defin ition of the mononuclear phagocyte system that short lived, bone marrowderived monocytes are required to replenish tissue macrophages 4 . Monocytes have long been known to contribute to the tissue macrophage pool, particularly during infection and inflam mation 5 . However, the relative contribution of monocytes to tissue macro phage populations in the steady state has been under scrutiny. Increasingly sophisticated experi ments with fatemapping technology, adoptive transfer, and parabiosis models have helped to improve our understanding of the complex contributions of dif ferent cell lineages throughout embryological develop ment to haematopoiesis and the seeding of tissues with resident macrophage precursors. Data now indicate that monocytes have a minimal contribution to most tissueresident macrophage pools in the steady state or even under certain inflammatory conditions. Many tissueresident macrophage populations have now been identified, but tissuespecific differences cannot yet be fully explained.
Tissue macrophage ontogeny can be divided into the early 'primitive' and subsequent 'definitive' haemato poietic waves 1 , with the bulk of experimental data derived from mouse models. Primitive haematopoiesis refers to early formation of haematopoietic progenitors -includ ing macrophage progenitors (or 'primitive macro phages') and erythromyeloid progenitors -from blood islands of the yolk sac in mice 7 and rats 8 at embryonic day 8.5-9.0 (E8.5-E9.0), with subsequent colonization of the fetal liver at E10.0-E10.5 via the newly established circulatory system 9, 10 . Definitive haematopoiesis in the aorta-gonadmesonephros (AGM) results in the release of haemato poietic stem cells (HSCs) at E10.5, which then colonize the fetal liver (E11.0) 11 . Thus, from E11.0 to E11.5 the fetal liver becomes the dominant site of haematopoiesis 1 , before the initiation of bone marrowderived haematopoiesis.
Yolk sacderived primitive macrophages colonize tissues such as brain, spleen, pancreas, kidney, heart and lungs 6, [12] [13] [14] [15] . Fetal liver monocytes derived directly from cMyb + erythromyeloid progenitors generated in dorsal aortic endothelial cells 16 subsequently add to the tissue resident macrophage population. Exceptions to this fetal monocytic infiltrate includes the central nervous system, where fetal liverderived monocytes do not contribute to the microglial cell population 13 ; the skin, where dual origin macrophages contribute to the Langerhans cell pool 17 ; and the gut, which seems to remain dependent on constant renewal from blood precursors, with data suggesting that circulating blood monocytes contrib ute to the pool of macrophages and dendritic cells in the intestine 18, 19 .
Monocyte development
Monocyte development and survival depends on colony stimulating factor 1 (CSF1; also known as MCSF) and its receptor CFS1R (also known as CD115) [20] [21] [22] . Embryonic and adult haematopoiesis in the steady state results in monocyte development from myeloid precur sor cells found in primary lymphoid organs, including fetal liver and bone marrow 1 . In addition, in mice under some inflammatory conditions the spleen has been shown also to contribute to monocyte production from precursor cells 23, 24 .
Following the establishment of bone marrow progeni tors, macrophage and dendritic cell precursors (MDP) -defined as lineagenegative (Lin − ), CD117 + (also known as KIT), CD135 + (also known as FLT3), and CSF1R + -give rise to monocytes, macrophages, and dendritic cells 25 . However, the absolute requirement for MDP as a common precursor for monocyte and macrophage lineages and resident dendritic cells is debated 26 . A potential additional monocyte precursor, termed the common monocyte progenitor (cMoP), has been identi fied 27 . cMoPs derive from MDPs, and are characterized by a reduction in the relative expression of CD135 (that is, cMoPs are Lin − CD117 + CD135 − CSF1R + ) 27 . cMoPs give rise to mature monocytes in the bone marrow. These mature monocytes do not subsequently differen tiate into either classical dendritic cells or plasmacytoid dendritic cells 27 . Thus, in the adult, monocytes can arise from the bone marrow via myelopoiesis. Myelopoiesis begins from haemato poietic stem and progenitor cells (HSPCs), which give rise to common myeloid progeni tors (CMPs), which in turn give rise to granulocytemacrophage progenitors (GMPs) and then cMoPs (FIG. 1) . During times of stress, such as infection, the myeloid branch of haematopoiesis can be expanded to increase monocyte production through the action of a number of wellcharacterized cytokines 5 . This process is also important in chronic inflammatory dis orders, including metabolic disorders and cardiovascular disease, where monocytosis is present (detailed below). Monocyte sub set production in the bone marrow and the factors influ encing blood trafficking and extravasation into tissue are represented in FIG. 1.
Blood monocytes
Circulation in the blood is a defining characteristic of a monocyte. Although previously considered inter mediary cells awaiting stimuli towards terminal dif ferentiation into a macrophage, dendritic cell, or other tissue descendant 4, 28, 29 , blood monocytes are now known to be a heterogeneous population of cells with differing steadystate phenotypes and as effector cells in response to microbial stimuli 3 . Furthermore, monocyte gene expression profiles and functions are conserved across vertebrate species 30 . Monocytes can be characterized by the expression lev els of surface proteins, RNA expression profiles, and mor phology 3, [31] [32] [33] . Morphologically, monocytes are spherical cells with prominent surface ruffles and blebs, a large reni form nucleus with a small nucleolus 34 . Differences in size and granularity exist between subsets (detailed below), with 'nonclassical' monocytes much smaller in size and less granular than 'classical' monocytes 3 . Heterogeneity in monocytes exists in many species 35 , including humans, rats, mice, and pigs 32, [35] [36] [37] [38] [39] [40] [41] [42] . Two major monocyte subsets have been identified in mice -classical and non classical -and three subsets have been identified in humansclassical, intermediate, and nonclassical -with classi cal monocytes being the most abundant (~80%) (TABLE 1) . In mice, monocytes are commonly identified in flow cytometry analyses by their characteristic forward and side scatter profiles and expression of CD115 (REFS 43,44).
Key points
• The mononuclear phagocyte system comprises heterogeneous cells derived from fetal and bone marrow precursors • Seeding of fetal tissue macrophages is distinct from monocyte-derived macrophages, highlighting the independent effector functions of monocyte subsets • Dyslipidaemia, characterized by hypercholesterolaemia and/or hypertriglyceridaemia, increases the risk of cardiovascular disease • Dyslipidaemia increases the production of monocytes through myelopoiesis • Blood monocyte subsets under dyslipidaemic conditions change their behaviour and activation, and increase their extravasation in response to triglyceride-rich lipoproteins and cholesterol
Monocyte subsets can then be differentiated on the basis of expression levels of a number of surface mark ers, including lymphocyte antigen 6C (LY6C), CC chemokine receptor type 2 (CCR2), CD43, and CX 3 C chemokine ligand 1 (CX 3 CR1) 1, 38, 43 . 
CD16
high in humans -subsets. Production and emigration of monocyte subsets depend on defined signals and chemokine receptors, such as C-C motif chemokine 2 (CCL2) 36, 80 , C-C chemokine receptor type 2 (CCR2) 15, 36, 38, 73, 248, 249 , and C-X-C chemokine receptor type 4 (CXCR4) 59 6 and in the setting of murine myocardial infarction and healing 53 , although this transition is yet to be confirmed in other species and under different environmental conditions. Monocyte ontogeny remains enigmatic, particularly in the con text of subset origins. For instance, what the halflife of monocytes is and where monocytes eventually go are still unclear. The current hypothesis is that both sub sets develop from bone marrow progenitors. However, as mentioned previously, data in mice suggest that, in the steady state, LY6C high monocytes can give rise to LY6C low monocytes 6 , both in the bone marrow and in the blood, although definitive evidence of a linear relationship between both monocyte subsets is lack ing. Conversion of LY6C high to LY6C low is further sup ported by stark differences in mouse monocyte subset survival. Turnover of LY6C high monocytes is thought to be 1 day, whereas LY6C low monocytes can survive from 2 days to as long as 2 weeks under certain con ditions 6 . The transcription factor nuclear receptor subfamily 4 group A member 1 (NR4A1; also known as NUR77) has an essential role in the development and survival of LY6C low monocytes 54 . LY6C low mono cytes have significantly higher amounts of NR4A1 than LY6C high cells at both the transcriptional and protein levels 54 . Nr4a1 −/− mice lack LY6C low monocytes in the bone marrow, blood, and spleen, and do not have any patrolling monocytes as assessed by intravital micro scopy 55 . Moreover, MDP precursors that would usually give rise to blood LY6C low monocytes do not do so in NR4A1deficient mice 54 . These data suggest that either NR4A1 is involved in monocyte 'conversion' or that mature LY6C high monocytes are actually not the precur sors of LY6C low . One might speculate that three mono cyte subsets exist in mice: bona fide LY6C high , LY6C low matured from LY6C high cells, and LY6C low patrolling monocytes at the endothelial interface derived from the differentiation of precursors driven by NR4A1 (FIG. 1) . Experiments are underway to examine this hypothesis.
Interestingly, homozygous deletion of Nr4a1 has been shown to accelerate atherosclerosis in the highfat diet (HFD)fed Ldlr −/− mouse model of atherosclerosis in some studies 56, 57 , but not others 58 . Finally, definitions of monocyte subsets might be further complicated by reports showing that LY6C high monocytes can be defined by expression of CXC chemokine receptor type 4 in the bone marrow, giving rise to further functional sub sets 59 , and that a subpopulation of LY6C high monocytes gives rise to inflammatory dendritic cells 60 . Moreover, an 'atypical' monocyte with neutrophil characteristics might be involved in fibrosis 61 . More work is needed to characterize the plasticity of monocytes.
Monocyte functions
Although the precise functions of monocyte subsets are yet to be defined, clear evidence supports subset specific functions. In mice, classical LY6C high mono cytes are rapidly recruited to sites of inflammation, extra vasate, and differentiate into monocyte derived macrophages 52 . By contrast, mouse nonclassical LY6C low monocytes, similarly to their human counter parts 3 , crawl and patrol the luminal side of the vascular endothelium 37, 55 , as shown by intravital microscopy. Evidence showing the differentiation of LY6C low mono cytes from LY6C high monocytes, the longer halflife of the LY6C low subset, and its patrolling role have led some investigators to suggest that these cells are termin ally differentiated 'blood macro phages' rather than blood monocytes 1 . However, we and other researchers have shown that these monocytes can migrate out of the blood during dyslipidaemia (detailed below) or auto immune inflammation [62] [63] [64] , implying that LY6C low monocytes are not terminally differentiated cells and can continue to respond to tissue cues. Similarly, the question remains whether the highly mobile, respon sive LY6C high monocytes that extravasate into the tissue might not always differentiate into macro phages or dendritic cells, and can uptake antigens as part of a tissuesurveillance function 47 .
Nonclassical LY6C
low monocytes, by patrolling the endothelium, also have surveillance functions. Through expression of surface molecules such as CD11a (also known as integrin α L ) 55 , CX 3 CR1 (REF. 37 ), intercellular adhesion molecule (ICAM) 1 and ICAM2 (REFS 36, 65) , and protein CYR61 (also known as CCN1) 66 , LY6C low monocytes remain in close proximity to the endothe lium and can respond to endothelial damage, perhaps monitoring endothelial integrity and responding to 
ATP-binding cassette transporters
Actively transport molecules into or out of cells. An example is the ABCA1 transporter that has a role in cholesterol export to HDL.
deposited immune complexes by recruiting inflam matory neutrophils 55, 67 . Moreover, these surveying monocytes might remove luminal vascular βamyloid deposits, as shown in a murine model of Alzheimer dis ease 68 . Nonclassical monocytes have also been shown to scavenge metastasizing tumour cells in a lung tumour mouse model 69 . More work is needed to identify the unique functional properties of nonclassical LY6C low monocytes. Whether these nonclassical monocytes have a direct role in cardiovascular disease is unclear, although these monocytes have been shown to patrol along the coronary vascular tree 70 .
Monocytes in atherosclerosis
Atherosclerosis is a dynamic and chronic inflamma tory disease, and thus seems to elicit very different responses from blood monocytes and tissueresident macrophages compared with traditional inflammatory scenarios. Preclinical models of atherosclerosis involve homozygous deletion of genes encoding proteins associ ated with lipoprotein clearance, namely Ldlr and Apoe, in order to generate chronic hyperlipidaemia and the formation of atherosclerotic plaques. These models have helped to shed light on monocyte production, migra tion into the atherosclerotic plaque, and subsequent develop ment of lipidladen macrophage foam cells (FIG. 2) . In these preclinical models, the hypercholestero laemic environment [71] [72] [73] [74] or the disruption of cholesterol efflux mediated by ATP-binding cassette transporters 75, 76 promotes monocytosis, an observation consistent with the monocytosis found in people with cardio vascular disease [77] [78] [79] . This increase in blood monocytes is a result of an expansion of the bone marrow progenitors HSPCs, CMPs, and GMPs. Importantly, use of competi tive bone marrow transplantation experiments allowed the track ing of the HSPC progeny into the athero sclerotic lesion, revealing a preferential accumulation in atherosclerotic lesions of Apoe −/− monocytes and macrophages com pared with wildtype cells 71 . Interestingly, monocytosis in the bone marrow and blood compartments might be dependent on chemokine signalling, specifi cally mediated by CC motif chemokine 2 (CCL2), CCR2, CC chemokine receptor type 5 (CCR5), and CX 3 CR1 (REFS 73, 80) . Moreover, these chemokines have a pro atherogenic role, as shown by the reduction in athero sclerotic plaque size following combined inhibition of CCL2, CCR5, and CX 3 CR1 despite high total choles terol levels present in Apoe −/− mice 80 . These studies on athero genesis subscribe to the dogmatic model of circulating monocyte extravasation and differentiation into macro phages, followed by subsequent accumula tion in macrophages of modified lipids via scavenger receptor uptake to generate foam cells. Bone marrow transplantation models in atherosclerosisprone mice indicate that an 'inflammatory' (LY6C high ) monocyte subset is readily recruited into the arterial intimal layer 81, 82 . Atherosclerosis progression depends on the presence and viability of this monocyte subset, and recruitment from this monocyte pool continues during lesion growth [81] [82] [83] . Importantly, this inflammatory or classical subset is the predominant subset to extravasate during atherogenesis. However, reports show non classical LY6C low monocytes also migrate to discrete athero sclerotic regions 84 . This migration might be important during specific types of dyslipidaemia associ ated with atherosclerosis, such as hypertriglycerid aemia, which has been associated with increased tissue recruitment of nonclassical monocytes 63 . The idea that plaque macrophages arise strictly from continued recruitment of blood monocytes has been challenged. In 2013, a study demonstrated through a series of elegant experiments that mainten ance and expansion of the lesional pool of macro phages in established lesions is mainly sustained by local cell proliferation rather than by continuous recruitment of blood monocytes 2 (FIG. 2a) . Interestingly, the study also showed that the macrophage area in the grow ing lesions remained unchanged 2 . These paradoxical results are difficult to reconcile, but an explanation might be that most of the newly recruited monocytes undergo rapid cell death, whereas a small pool of macro phages proliferate but then die after a few divi sions 44 . However, in contrast to the shortterm experi ments, longterm followup revealed that almost all lesional macrophages were replaced by newly recruited cells 2 . Collectively, the findings from this study high light the importance of monocyte recruitment, macro phage proliferation, and macrophage death during atherosclerosis progression 85 . A population of tissueresident macrophages, termed adventitial macrophages, has been identi fied in the arterial adventitia 86 . In adulthood, these adventitial macro phages derive from a pool of adven titial macrophage progenitor cells 86 . These adventitial macro phages also derive embryonically from CX 3 CR1 + erythromyeloid progenitors (from the yolk sac) and from fetal liver monocytes 87 . Interestingly, the adven titial macrophage population has been shown to expand in the setting of hyperlipidaemia 86 . However, these adventitial macrophages seem to be a minority within the macrophage pool in the atheroma 86 , but might have an important indirect role through the release of cytokines or by inducing neovascularization.
The above studies focused on plaque macrophage populations during atherogenesis. However, recurrent insults, such as those frequently following an acute myocardial infarction (MI), initiate an additional wave of altered haematopoiesis 88 . Interestingly, an increased macrophage burden was observed within atherosclerotic lesions after an acute MI 88 . The increase in macrophage burden was independent of local cell proliferation and was a result of enhanced monocyte recruitment from the spleen 88 . The acute MI causes sympathetic over drive, which mobilizes HSPCs from the bone marrow into the spleen, where HSPCs undergo extramedullary haematopoiesis and give rise to monocytes that are then involved in atherosclerosis 88 . Furthermore, in addition to the role of blood monocytederived macrophages in atherosclerotic lesion progression, monocytes and macro phages with mixed ontogenies are important in driving an inflammatory response and subsequent repair of the myocardium after an acute MI 89 . Dyslipidaemia Dyslipidaemia encompasses blood lipid levels beyond the normal range either elevated or decreased
; however, dyslipidaemia is most commonly applied when lipid levels associated with cardio vascular disease are elevated, such as LDL, or when low levels of HDL cholesterol are found 90 . Elevations in blood cholesterol levels, in particular, are linked with an increased risk of cardiovascular disease 91 . The blood lipid pool is made up of lipoproteins that transport cholesterol, cholesteryl esters, and fatty acids (predominantly as triglycerides) to muscle, adipose tissue, and to the liver for processing and clearance 
Reverse cholesterol transport
Transport of cholesterol from tissues or cells back to the liver for clearance. Cholesterol can be transported via ABCA1 to HDL, which acts as an acceptor molecule. This process is thought to be cardioprotective.
(thought to be lipidladen macrophages) 93 . Fatty acids have also been shown to accumulate in the athero sclerotic plaque 94 . Interestingly, this accumulation is dynamic and the composition of the fatty acid pool changes over time, which might provide selective stim uli to foam cells and represent a dietary influence on plaque composition 94 . 97 and US (ACC/AHA) 98 associ ations do not focus on such classifications, although these guidelines often retain the names proposed by Frederickson. The guidelines instead recom mend testing and treatment if lipo protein parameters and other clinical features are suggest ive of an inherited, familial dyslipid aemia. Familial hyper cholesterolaemia is a monogenic disorder and most strongly correlates with cardio vascular disease, but most inherited lipid disorders are poly genic 99 . Individuals with familial hypercholesterolaemia can have the homozygous or heterozygous form of the disease, which correlates with both severity of the LDL abnormality and the risk of cardiovascular disease 100, 101 .
Classification
Dyslipidaemias can be classified as primary if the dys lipidaemia has a genetic cause (familial or inherited dyslipid aemia) or as secondary if the dyslipidaemia results from other medical conditions (BOX 1). The Frederickson classification 95 of familial dyslipidaemia has been adopted by the WHO 96 , and remains one of the most frequently used in clinical decisionmaking. However, this classifi cation does not account for HDL status or for gene vari ants associated with abnormally elevated lipid levels. For this reason, guidelines by European (ESC/EAS)
Dyslipidaemia in cardiovascular disease
Hypercholesterolaemia. The association between high LDLcholesterol levels in blood and the develop ment and progression of cardiovascular disease has been known for >100 years 102, 103 . Discovery of the LDL receptor and subsequent development and success of LDLlowering drugs, such as statins, have shown a con vincing link between LDLlevel reduction and reduc tions in cardiovascular morbidity and mortality [104] [105] [106] [107] [108] . Beyond the extensively used statin therapy -which lowers blood cholesterol levels through inhibition of 3hydroxy3methylglutaryl CoA reductase, an impor tant and ratelimiting step in cholesterol synthesis in the liver -newer, alternative LDLlowering agents, such as ezetimibe (inhibits Niemann-Pick C1like 1 resulting in reduced absorption of cholesterol in the small intestine) have also been shown in clinical trials to improve cardio vascular outcomes after MI 109 . These findings suggest that the reduction in the risk of cardiovascular disease is not unique to statins and probably extends to alternative LDLlowering strategies. For example, a potential alter native strategy is to target oxidized LDL (oxLDL), which has been shown to induce a proinflammatory response in monocytes in vitro [110] [111] [112] , and whose circulating levels are elevated in cardiovascular disease [113] [114] [115] [116] . HDL as a therapeutic strategy. Beyond LDL levels, inter est in HDLcholesterol levels as a potential thera peutic tar get has been explored, mainly owing to the role of HDL in reverse cholesterol transport (RCT), and to its anti oxidative and antiinflammatory properties 117 . HDL promotes cellu lar cholesterol efflux by interaction with the ATPbinding cassette transporters ABCA1 and ABCG1 (REFS 118-121). The ratio of total cholesterol to HDL level is used as a predictive tool in assessing the risk of cardiovascular dis ease 122 . The consistent inverse relationship between HDL levels and the risk of cardio vascular disease 123 prompted optimism into research aimed at elevating blood HDL levels. However, clinical trials on therapies aimed at rais ing HDL levels to reduce the risk of cardio vascular dis ease have been largely disappointing [124] [125] [126] [127] [128] [129] . These negative findings are supported by a Mendelian randomization study showing that individ uals with a single nucleotide polymorphism (SNP) in LIPG that results in elevated HDL levels in blood (approximately a 12% increase) was not associated with a reduction in the risk of MI 130 . Furthermore, other SNPs associated with lifetime eleva tions of HDL also did not correlate with a reduction in the risk of MI 130 . However, evidence now shows that static measurements of HDL alone are not necessarily an accur ate assessment of the functional role of HDL particles. For instance, HDL particle size 131 and efflux capacity 132 might be better predictors for assessing the role of HDL in altering the risk of cardiovascular disease.
Hypertriglyceridaemia. Despite some early interest in the role of dietary triglycerides in the risk of cardio vascular disease [133] [134] [135] [136] [137] [138] , epidemiological data do not support a substantial link between the levels of triglycer ides in blood and the risk of cardiovascular disease 139 . Moreover, pharmaco logical methods for reducing ) by inducing proliferation of bone marrow precursors, which in turn leads to blood monocytosis, endothelial dysfunction, and increased recruitment mediated by chemokine receptor signals such as C-C chemokine receptor type 5 (CCR5) 80, 251 , and ultimately leads to increased tissue monocyte-derived macrophages. Hypertriglyceridaemia increases accumulation of patrolling nonclassical monocytes (LY6C low ) and extravasation, possibly mediated by C-C motif chemokine 4 (CCL4) 63 . Dyslipidaemia might lead to increased proliferation of tissue-resident macrophages. Monocytes can endocytose circulating lipids, leading to formation of 'foamy' monocytes, which might then deliver lipids from the blood to peripheral tissues, contributing to increased lipid retention in tissues (via heparin sulfate proteoglycans; HSPGs) and to increased lipid endocytosis by tissue macrophages, promoting foam cell formation. Red lines indicate pathways upregulated in dyslipidaemia. Dotted lines represent hypothesized or unknown pathways. b | Lipids can enter the cell via regulated uptake, mediated for example by LDL receptor (LDLR) and LDLR-related protein 1 (LRP1), or via unregulated uptake, mediated among others by scavenger receptors such as CD36 and SRA1, and by Toll-like receptors (TLRs). Neutral lipids and cholesterol can then accumulate inside the cell, leading to proinflammatory or anti-inflammatory responses depending on the lipid species and lipid modification. Lipid entry also leads to activation of intracellular cholesterol storage and efflux pathways (reverse cholesterol transport). Increased lipid loading modulates the cytoskeleton by blocking signalling components such as RAS homologue gene family member A (RHOA), leading to defects in migration and possible tissue retention of macrophages 62 . ABCA1, ATP-binding cassette transporter subfamily A member 1; ABCG1, ATP-binding cassette transporter subfamily G member 1; CXCL16, C-X-C motif chemokine 16; LOX1, lectin-type oxidized LDL receptor 1; LPL, lipoprotein lipase; LXR, liver X receptor; mmLDL, minimally modified LDL; oxLDL, oxidized LDL; NEFA, nonesterified fatty acid; RXR, retinoid X receptor; TG, triglycerides; TGRL, triglyceride-rich lipoprotein; VLDL, very low-density lipoprotein.
◀ triglyceride blood levels with the aim of decreasing the risk of cardiovascular disease in addition to the risk reductions achieved with statins have been unsuccess ful so far 140 . Nevertheless, lowering triglyceride levels as a therapeutic strategy is experiencing renewed interest on the basis of findings from Mendelian randomization analyses [141] [142] [143] , genomewide association studies 144, 145 , and studies on SNPs 146 suggesting that the residual risk of cardio vascular disease that persists despite achievement of target LDL levels is related to elevated triglyceride levels, rather than low HDL levels.
Effect of dyslipidaemia on monocytes
A number of studies have examined the changes in the phenotype of monocytes in response to lipids, predomin antly in the context of atherosclerosis models 62, 63, [147] [148] [149] [150] [151] [152] [153] [154] .
Although mechanisms associated with atherogenesis remain the focus of much work, the effect of dyslipid aemia (that is, variance in particular lipid species) on monocyte phenotype and function might be more com plex. Possible effects of dyslipidaemia on immune func tion include human data showing that surgical patients with either very high or low total cholesterol levels were at an increased risk of infection, suggesting an apparent immunoparesis in these patients 155 .
Multiple experimen tal data show poor responses of both innate and adaptive immunity to fungal and bacterial infection in transgenic mice with dyslipidaemia [156] [157] [158] . Indeed, leukocyte inter action with lipids in hyperlipidaemic environments has been documented for >50 years, when lipidfilled rat monocytes in response to a HFD were denoted as 'lipophages' (REF. 159 ), and monocyte invasion of the vascu lar endothelium in HFDreared pigs was imaged by transmission and scanning electron microscopy in 1979 (REF. 160 ) and 1981 (REF. 161 ), respectively. Some studies in zebrafish have also shown that monocytes can uptake lipids in circulation in a TLR4dependent process 162 .
Effects of cholesterol.
The presence of cholesterol within the atherosclerotic plaque and the identification of monocyte extravasation into the subendothelial space has focused the trajectory of much monocyte research in this pathophysiological context. Elevation in blood cholesterol, predominantly owing to raised LDL levels, is the most commonly studied dyslipidaemic condition. As monocytes and lipoprotein particles both circulate in the blood, monocytes are likely to have physical encoun ters with cholesterol well before monocytes migrate into the atherosclerotic lesion and differentiate into tissue macro phages. In most of the literature in this field, the term 'monocyte' is often used interchangeably with (monocyte derived) 'macrophages' , and experimental models are often in vitro scenarios and/or cell lines that are used to recapitulate potential pathophysiological conditions. Additionally, these experiments frequently involve transgenic animal models in which cholesterol levels are dramatically elevated to obtain results within an acceptable timeframe. Therefore, data from experimental studies should be interpreted with some caution when translating into the human clinical context.
Monocytes undergo morphological, phenotypi cal, and functional changes in hypercholesterolaemic environ ments. Work in patients with familial hyper cholesterolaemia demonstrated intracytoplasmic vacuo lation in monocytes and suggested the presence of monocytosis in these patients 163 . CD14 high CD16 low (classical) monocytes from patients with familial hyperc holesterolaemia preferentially take up oxLDL 164 . Exposure of these monocytes to oxLDL induces an increase in the levels of the macrophage marker CD68 and the activation marker CD11c (also known as integ rin α X ), and an improved capacity for phagocytosis 164 . Human monocytes have been shown to uptake LDL in vitro, but do so more readily with oxLDL via scaven ger receptors, including SRA1, SRA2, SRB1, CD36, and lectinlike oxidized LDL receptor 1 (LOX1) 165, 166 (FIG. 2) .
Transgenic animal models of elevated total cholesterol total cholesterol, LDL cholesterol, and triglycerides (TG).
Hypertriglyceridaemia
• Hypertriglyceridaemia is an aberrantly elevated level of TG in the blood (normal <1.7 mmol/l, high 1.7-9.9 mmol/l, severe >10 mmol/l). TG are the bulk form in which fatty acids (fat) are transported in the blood. TG are packaged into lipoproteins, predominantly in chylomicrons and very-low density lipoproteins (VLDL).
Chylomicrons transport the bulk of dietary fat, whereas VLDL transport fatty acids coming from the diet (exogenous) and produced in the body (endogenous).
• Elevated levels of nonfasting TG are correlated with increased risk of cardiovascular disease 141, 142, 144, 145 .
Hypercholesterolaemia
• Hypertriglyceridaemia can be found in isolation or in addition to elevated levels of cholesterol (hypercholesterolaemia). Of note, elevated cholesterol levels refer to levels of cholesterol-carrying lipoproteins, LDL and HDL.
• High LDL levels strongly correlate with increased risk of cardiovascular disease 100, 101, [104] [105] [106] [107] [108] . Conversely, high HDL levels might be correlated with a reduced risk of cardiovascular disease 123 .
Classification
Hyperlipidaemia can be caused by primary (genetic) factors or by secondary (nongenetic) factors such as lifestyle habits or medical conditions.
• Genetic (primary) hyperlipidaemia.
-Familial combined hyperlipidaemia. Polygenic cause. Elevation of LDL, TG, or both.
-Familial hypercholesterolaemia (heterozygous or homozygous). Mutation in LDLR that leads to elevated levels of LDL cholesterol. -Familial dysbetalipoproteinaemia. Autosomal recessive. The most frequent cause is homozygous mutation in APOE. Elevated total cholesterol and TG. Associated with metabolic syndrome. -Hypertriglyceridaemia. Common and rare genetic variants. Moderate severity (blood TG levels 2-10 mmol/l) caused by polygenic effect influencing VLDL production and removal. Monogenic causes: APOA5, APOC2, GPD1, GPIHBP1, LMF1, LPL. A gain-of-function mutation in APOC3 leads to high blood levels of apolipoprotein C-III/TG. -Other genetic disorders of lipoprotein metabolism, for example, Tangier disease (very low levels of HDL).
• Secondary hyperlipidaemia.
-Several factors can cause hyperlipidaemia, such as lifestyle habits (high fat diet, physical inactivity, alcohol consumption) 238, 239 , medical conditions including diabetes mellitus 240 , hypothyroidism 241 , and some forms of kidney disease 242, 243 , and the use of certain drugs (such as antihypertensive agents 244 , hormone replacement therapy 245 , contraceptives 246 , and some antipsychotic drugs 247 ).
Neutral lipid droplets
Lipids without a polar charge that can be found within cells, and commonly refers to cholesteryl esters and triglycerides.
NLRP3 inflammasome
An important oligomer molecule that forms part of the cellular inflammatory response, particularly in innate immune cells. Its activation results in the release of cytokines such as interleukin-1β.
Minimally modified LDL
A unique form of oxidized LDL enriched with aldehyde-containing phosphatidylcholines.
Reconstituted HDL
A synthetic form of HDL used to improve cholesterol transport out of the cell (efflux) with potential therapeutic value in cardiovascular disease.
Chylomicrons
Also known as 'ultra-low density lipoprotein', these large lipoprotein particles are secreted by gut endothelial cells and predominantly transport dietary lipids (triglycerides and cholesterol) in the circulation. Chylomicron levels rise after dietary intake of fat or carbohydrate and fall after fasting.
Very low-density lipoprotein
These lipoproteins predominantly transport triglycerides produced by the body (muscle, liver), but can also be altered by dietary fat intake.
show evidence of neutral lipid droplets in monocytes 62, 84, 147 and, although the most probable explanation for this finding is lipid uptake, the mechanisms remain unclear, and de novo lipogenesis (described in monocytederived macrophagelike cells 167 ) remains a possibility. Atherosclerosis has long been considered an inflam matory condition 168 , and the identification of cholesterol crystals not only in mature atherosclerotic plaques, but also in early atherosclerotic plaques 169, 170 , adds weight to the notion that cholesterol might drive inflammatory atherogenesis (FIG. 2) . Cholesterol crystals can induce the release of IL1β through activation of the NOD, LRR and pyrin domaincontaining 3 (NLRP3) inflammasome in preprimed mononuclear cells in vitro 169 . Activation of the NLRP3 inflammasome and release of active IL1β requires two signals. The first (priming) signal is required for the upregulation of NLRP3 and proIL1β, and can be trig gered, for example, by TLR activation. The second signal induces the activation of the inflammasome and caspase 1 to cleave proIL1β. Minimally modified LDL (mmLDL), which provides a chemotactic stimulus to monocytes 171, 172 , has also been shown to provide a priming signal for mono nuclear cells in vitro 169 . Interestingly, the dietary saturated fatty acid palmitic acid induced TLR2mediated IL1β release in a human monocytic cell line in vitro, a process that was abrogated by use of the poly unsaturated fatty acid docosa hexaenoic acid 173 . Similarly, TLR4 activation induced by oleic acid and palmitic acid has been reported in macrophage cell lines 174 . TLR4 (REFS 175, 176) and its downstream signalling adaptors TIR domaincontaining adaptor molecule 1 (TICAM1, also known as TRIF) and TIR domaincontaining adaptor molecule 2 (TICAM2, also known as TRAM) 177 have been implicated in athero sclerosis. TLR4 stimulation generally results in activ ation of nuclear factor (NF)κB, and NFκB activation can either provide proinflammatory atherosclerotic stimuli or be atheroprotective depending on the initial route of activation 178, 179 . A report published in 2016 suggests an alternative pathway of NLRP3 inflammasome activation in human monocytes that does not require a second signal when stimulated through lipopolysacchar ide (LPS)-TLR4 signalling 180 . However, atherosclerosis might occur inde pendently of NLRP3 signalling 181 , supporting the notion that inflammasome activation is not ubiquitous in the plaque. OxLDL is thought to induce activation of TLR2, TLR4, and TLR6 mediated by CD36 signalling 182 , which in turn can activate macrophages 183 . OxLDL can inde pendently promote the differenti ation of human mono cytes into macrophagelike cells in vitro [184] [185] [186] . Moreover, oxLDL might induce monocyte reprogramming or 'innate immune memory' that might alter secondary ligand responses 112 . Some data suggest that cholesterol is not always an inflammatory stimulus. Intermediates of the cholesterol biosynthetic pathway, such as desmosterol, provide an antiinflammatory stimulus via liver X receptor (LXR) signalling in elicited peritoneal macrophages from Ldlr −/− mice 187 (FIG. 2b) . Whether these cholesterol inter mediates have antiinflammatory potential in monocytes is unknown. Of note, other fatty acids that are present in neutral lipiddroplets of foamy monocytes, such as palmitoleic acid, have also been shown to have anti inflammatory functions 188 . The cholesterol efflux trans porter ABCA1 might also have an anti inflammatory role by modulating TLR signalling. In murine macrophages, ABCA1 reduces TLR trafficking to lipid rafts by redu cing lipid raft cholesterol content 189 . This finding also supports an antiinflammatory role of HDL cholesterol. Furthermore, cell cholesterol removal by choles terol efflux pathways and administration of reconstituted HDL have been shown to have direct antiinflammatory effects on leukocytes 117, 190, 191 , and in the production of classical monocytes by acting on HSPCs 76 . A study pub lished in 2016 showed the specific immuno modulatory effects of apolipoprotein AI (the main HDL apolipo protein) on monocyte behaviour 192 . Acute exposure to apolipoprotein AI inhibited macro phage chemotaxis in vitro and monocyte recruitment in vivo 192 , consistent with previous findings 117 . The different aspects of choles terol, inflammation, and immune interaction have been reviewed previously 193 .
Effects of triglyceride-rich lipoproteins.
For the purposes of this section, triglyceriderich lipoproteins (TGRLs) are defined as lipoprotein particles predominantly com prising chylomicrons, chylomicron remnants, and very low-density lipoprotein (VLDL). Most of the research in blood lipid abnormalities has focused on the effects of LDL and monocyte/macrophage responses. However, some studies have addressed the effects of TGRLs on blood monocytes. Fluctuations of chylomicron levels and, to a lesser degree, VLDL levels occur after ingesting lipidrich or carbohydrate rich meals 194, 195 . Importantly, people, especially those in Western countries, spend much of their day in the postprandial state owing to increased snacking associated with obesity 196 . Allied to this concept, the role of nonfasting triglyceride levels as a risk predictor for cardio vascular disease has been shown to be of value, and is endorsed by the European Atherosclerosis Society (EAS) for clinical assessment 197 . Furthermore, beyond their potential role in atherosclerosis, elevated blood lipid levels are found in individuals with HIV 198 and in conditions characterized by chronic inflammation, such as systemic lupus erythematosus 199 , implying potential alternative interactions between dysregulated immune cells in these conditions and the presence of elevated blood lipid levels.
Ldlr −/− mice are frequently used to study the effects of dyslipidaemia on innate immunity. These mice unsur prisingly have elevated LDL levels; however, these mice also have markedly elevated levels of the chylomicron and VLDL subfractions (which are rich in both apolipo protein B100 and apolipoprotein B48), suggesting elevations in TGRLs 200 . VLDL is composed predomin antly of trigly cerides (>70%), but has a small proportion of cholesterol content (>10%) 201 , some of which can be influenced by dietary intake 194 . A study published in 2016 demonstrated the appearance of neutral lipid droplets in monocytes (both subsets) from Ldlr −/− mice maintained on a HFD compared with monocytes from mice fed a control chow diet, with evidence of impaired monocyte migration and retention in extravascular tissue in response to inflammation 62 . This phenotype of tissue retained monocytes after lipid loading might be related to the plaque macrophage retention seen during HFD induced atherosclerosis models 202, 203 . . The accumulation of neutral lipids is associated with an impairment in chemotaxis and chemokinesis in in vitro assays, potentially explained by alterations in cyto skeletal rearrangement modulated by the small GTPase RAS homologue gene family member A (RHOA) 62 (FIG. 2b) .
However, in mouse models, in vivo monocyte lipid accumu lation did not result in altered patrolling behavi our 62 , which suggests that defects in migration after lipid loading could be restricted to the extra vascular tissue compartment. In vivo work in mouse models in which chronic TGRL elevation is induced pharmaco logically support a more complex role for nonclassical LY6C low monocytes. Administration of poloxamer407 elevates circulating triglyceride levels in wildtype mice by inhib iting lipoprotein lipase (LPL) -which cataly ses the conversion of VLDL to inter mediatedensity lipo protein (IDL) -and cholesterol 7α hydoxylase (CYP7A1) -involved in the transformation of choles terol into bile acids -without causing apparent hypercholesterol aemia 63, 205 . This model of hypertriglyceridaemia results in a noticeable reduction in peripheral counts of non classical LY6C low monocytes owing to the increase in their crawling behaviour and endothelial retention (without alteration of bone marrow cMoP, total monocyte, or sub set numbers) 63 . This increase in crawling and retention led to mass monocyte extra vasation into all organs examined (heart, liver, and kidney) and accumu lation of F4/80 + CD68 + macrophages 63 . The exact mechanisms are unknown, but did not produce an overt inflamma tory response, although the model did involve the over expression in tissue macrophages of the chemokine CCL4 and a Gproteincoupled receptordependent mechanism 63 . Interestingly, in this model of poloxamer 407induced hypertriglyceridaemia, monocytes did not have intra cellular lipid accumulation, which might indi cate a role for LPL in lipid uptake or lipophage forma tion. Indeed, lipid droplet incorporation into monocytes might be mediated by LPL. LPL generates free, non esterified fatty acid from TGRLs that might promote an inflammatory phenotype, as shown in some studies 149, 206 . Taken together, these findings indicate that choles terol and TGRLs can influence monocyte subset effector functions (FIG. 2b) . Further work is required to under stand the potential effect of dyslipidaemic environ ments on immune functions and cardiovascular disease. Speculating that monocytes can deliver a lipid load dur ing atherogenesis, rather than the restricted theory of only tissue macrophages responding to retaining modi fied cholesterols, would be intriguing. The contribution of monocytes as effective lipid carriers, and indeed the role of monocytes in systemic lipid metabolism, warrants further study.
Effect of dietary lipids on monocytes
Contributions of dietary lipids to cardiovascular disease remain enigmatic, and any potential role of dietary lipids in modulating monocyte and macrophage bio logy has not been studied in detail. Dietary studies are inherently difficult to perform, as the majority require substitution of one dietary component while maintaining similar calor ific content. Analyses in dietary studies usually involve an element of observation, and are reliant on question naires and participant reporting; therefore, these studies are subject to numerous sources of bias. Despite these limitations, longterm and shortterm diet ary studies have helped to inform us of potential deleteri ous effects of dietary lipids. The effects of socalled 'healthy eating' on disease continues to be of interest, particularly its role in cardiovascular disease 207 . Diets rich in saturated fatty acids have been implicated in cardiovascular disease [208] [209] [210] [211] [212] [213] [214] [215] [216] , whereas monounsaturated fatty acids (MUFA) 214, 217, 218 and polyunsaturated fatty acids (PUFA) [219] [220] [221] are sug gested to be cardio protective. Whether dietary saturated fat is indeed associated with cardiovascular disease remains controversial, particularly in light of updated guidelines continuing to support a diet low in saturated fat 222 , even after several retrospective metaanalyses have found no link between the incidence of cardio vascular disease and saturated fat intake 221, 223, 224 . However, these studies support the notion that diets rich in transfat are deleterious to health and that MUFArich diets and omega3 PUFArich diets are beneficial 221, 223, 224 . Although these data help to establish epidemiological trends, these studies do not help to clarify the mech anisms by which dietary lipid might influence the risk of cardiovascular disease. Shortterm and acute feeding studies have been used to elucidate these mechanisms. Diets rich in saturated fat can activ ate proinflamma tory pathways in peripheral blood mononuclear cells 225 and in monocytes 149, 206, 226 , whereas MUFArich diets do not seem to induce inflammatory signalling path ways 225 . Possible mechanisms through which saturated fat might drive an inflammatory response are varied; for instance, saturated fat might promote trafficking of gut endotoxin into the systemic circulation [226] [227] [228] [229] , and although early in vitro data 174, [230] [231] [232] [233] and limited evidence in vivo 234 suggested that the mechanism might be medi ated through direct stimulation of TLR by saturated fat, other studies indicate that this mechanism is unlikely and show that the inflammatory response is a result of endotoxinaemia 235 . Immune cells are altered within hours of meal consumption. A meal rich in saturated fat can activate monocytes, as assessed by increased expression of CD11c, accumulation of cytosolic intracellular lipid analysed ex vivo, and increased adherence to vascular cell adhesion protein 1 (VCAM1) substrate in a shear stress model 149 . In flow cytometry analyses, human leuko cytes 236 and monocytes 149 isolated from blood in the postprandial phase show an increase in side scatter profile, implying an increase in granularity resulting from an increase in lipid internalization. Therefore, similarly to dyslipidaemic environments, the postprandial response of consuming a diet high in saturated fat might lead to formation of lipophages or 'foamy' monocytes 149, 154, 237 . A study published in 2016 showed that the postprandial response mediates monocyte activation in individuals with metabolic syndrome 153 . The detailed mechanisms of when and how monocyte subsets respond to dietary lipid loading remain to be determined.
Conclusions
In this Review, we have briefly discussed the role of fetal macrophages and embryonic monocytes in maintaining the tissueresident macrophage pool (FIG. 1) . The role of these fetal tissueresident macrophages in cardio vascular disease and response to dyslipidaemia remains to be fully explored. We have elaborated on the hetero geneity of bonemarrowderived mouse and human monocytes and some essential differences in subset effector functions during steady state and dyslipidaemia (FIGS 1,2) . The modulation of effector functions of blood monocytes during dyslipidaemia might increase the risk of athero sclerosis and accelerate the progression of the disease. In summary, dyslipidaemia -with differing effects of hypercholesterolaemia and hypertriglycerid aemia -can alter bone marrow production of monocyte precursors and mature monocyte subsets (particularly classical monocytes); promotes lipid endocytosis and accumulation of neutral lipid droplets in monocyte sub sets; induces an increase in endothelial accumulation and extravasation of nonclassical monocytes; increases tissue retention of monocytes and accumulation of tissue resident macrophages; and promotes a proinflammatory phenotype and modulates chemotaxis in monocytes (FIG. 2b) . Together, these responses could aggravate tissue damage during atherogenesis and, we hypothesize, this increased tissue damage might increase the risk of plaque rupture. This hypothesis requires more investigation, but does raise the possibility that lipidlowering therapies can modulate monocyte behaviour towards a response that might help to reduce cardiovascular events.
